Pfizer Inc. (NYSE:PFE) Shares Sold by Dodge & Cox

Dodge & Cox reduced its holdings in Pfizer Inc. (NYSE:PFE) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,385 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Dodge & Cox’s holdings in Pfizer were worth $3,351,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Truepoint Inc. grew its position in Pfizer by 13.2% during the third quarter. Truepoint Inc. now owns 8,714 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 1,017 shares during the period. Johnson Investment Counsel Inc. grew its holdings in shares of Pfizer by 6.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 161,336 shares of the biopharmaceutical company’s stock worth $5,352,000 after acquiring an additional 9,863 shares during the period. Kestra Advisory Services LLC increased its stake in Pfizer by 3.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 736,534 shares of the biopharmaceutical company’s stock valued at $24,431,000 after purchasing an additional 22,036 shares in the last quarter. Excalibur Management Corp raised its holdings in Pfizer by 2.5% during the third quarter. Excalibur Management Corp now owns 158,250 shares of the biopharmaceutical company’s stock worth $5,249,000 after purchasing an additional 3,878 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. acquired a new stake in Pfizer in the third quarter valued at $245,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4 %

NYSE PFE opened at $27.53 on Friday. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The business’s 50-day moving average price is $27.56 and its 200 day moving average price is $27.78. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.36.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the firm posted $1.23 EPS. The company’s revenue was down 19.5% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.10%. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

PFE has been the subject of several research reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Morgan Stanley raised their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.